Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May

A key Japanese health ministry panel will review whether to recommend approval of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma on February 26, and if it gets the clearance and all goes without a hitch, the typical timeline suggests...read more